AtaGenix

Emapalumab

  • 1
  • 2
ATAD00469
-
+
futures
Inquiry
  • Product Details
  • Bioactivity
  • Chemistry
  • How to order
  • Instructions
Catalog No.icon
ATAD00469
INN (International Nonproprietary Name)icon
Emapalumab
Purityicon
>95%
SDS-PAGE imageicon
    Concentrationicon
    5 mg/ml
    Formulationicon
    PBS buffer PH7.4
    Sourceicon
    CHO cells
    Endotoxin levelicon
    Please contact with the lab for this information.
    Noteicon
    For research use only .
    Descriptionicon
    Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.1,5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.5 As well, emapalumab was given the status of PRIME by the EMA.
    Alternative namesicon
    NI-0501,emapalumab-lzsg
    Specificity target name;speciesicon
    IFNG [Homo sapiens]
    Speciesicon
    Homo sapiens
    Receptor identificationicon
    IgG1-lambda
    CASicon
    1709815-23-5
    Storageicon
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Store at +4°C short term (1-2 weeks).
    Store at -20 °C 12 months.
    Store at -80°C long term.

    Guarantee and Disclaimer:

    After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

    When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

    When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

    The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.